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Peptides isolated from animal venoms have shown the ability to regulate pancreatic beta
cell function. Characterization of wasp venoms is important, since some components of
these venoms present large molecular variability, and potential interactions with different
signal transduction pathways. For example, the well studied mastoparan peptides interact
with a diversity of cell types and cellular components and stimulate insulin secretion via
the inhibition of ATP dependent Kþ (KATP) channels, increasing intracellular Ca2þ
concentration. In this study, the insulin secretion of isolated pancreatic islets from adult
Swiss mice was evaluated in the presence of synthetic Agelaia MP-I (AMP-I) peptide, and
some mechanisms of action of this peptide on endocrine pancreatic function were char-
acterized. AMP-I was manually synthesized using the Fmoc strategy, puriﬁed by RP-HPLC
and analyzed using ESI-IT-TOF mass spectrometry. Isolated islets were incubated at
increasing glucose concentrations (2.8, 11.1 and 22.2 mM) without (Control group: CTL) or
with 10 mM AMP-I (AMP-I group). AMP-I increased insulin release at all tested glucose
concentrations, when compared with CTL (P < 0.05). Since molecular analysis showed
a potential role of the peptide interaction with ionic channels, insulin secretion was also
analyzed in the presence of 250 mM diazoxide, a KATP channel opener and 10 mM nifedipine,
a Ca2þ channel blocker. These drugs abolished insulin secretion in the CTL group in the
presence of 2.8 and 11.1 mM glucose, whereas AMP-I also enhanced insulin secretory
capacity, under these glucose conditions, when incubated with diazoxide and nifedipine.
In conclusion, AMP-I increased beta cell secretion without interfering in KATP and L-type
Ca2þ channel function, suggesting a different mechanism for this peptide, possibly by G
protein interaction, due to the structural similarity of this peptide with Mastoparan-X, as
obtained by modeling.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Peptides occur in the whole animal kingdom and are
involved in most, if not all, physiological processes inx: þ55 19 3521 6185.
).
lsevier OA license.animals. The knowledge of the amino acid sequence of
peptide hormones or neurotransmitters is important for
the synthesis of large quantities of peptides, in order to
perform further functional analysis (Baggerman et al.,
2004). Wasp venoms are a rich source of peptides
involved in pain and local tissue damage, among other
effects. Some of these peptides can interact with G-protein
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tion of different types of basophiles, chemotaxis of poly-
morphonucleated leukocytes (PMNL), smooth muscle
contraction and neurotoxicity (Ishay et al., 1975; Nakajima,
1984; Oliveira et al., 2005; Rocha et al., 2008).
The most abundant classes of peptides, isolated from
wasp venoms, are the mastoparans, followed by antibiotic
and chemotactic peptides (Nakajima et al., 1986). Classi-
cally, peptides from the mastoparan group are reported to
be 10–14 amino acid residues long and to have an a helix
conformation (Nakajima et al., 1986; Mendes et al., 2005).
These peptides are also rich in lysine residues, which are
thought to perform a key role in the stimulation of hista-
mine release from mast cells (Higashijima et al., 1990),
serotonin from platelets and prolactin from the anterior
pituitary gland (Hirai et al., 1979a; Kuroda et al., 1980). In
addition, recent studies proposed the classiﬁcation of
peptides based on their physicochemical properties,
instead of primary sequence similarities (Saidemberg et al.,
2011).
Mastoparan, the ﬁrst peptide of this class, was reported
to be capable of stimulating the release of granules from
mast cells (Hirai et al., 1979a). However, different studies
have shown that this peptide can stimulate the degranu-
lation of other cell types, such as: MIN6 cells (Ohara-
Imaizumi et al., 2001), INS-1 cells (Amin et al., 2003) and
beta pancreatic cells (Gil et al., 1991; Komatsu et al., 1992,
1993; Hillaire-Buys et al., 1992; Eddlestone et al., 1995;
Konrad et al., 1995; Kowluru et al., 1995; Straub et al., 1998;
Kowluru, 2002; Amin et al., 2003; Chen et al., 2004; Omata
et al., 2005). Mastoparan can alter some of the biochemical
mechanisms involved in the secretory response of these
cells, enhancing, for example, the activity of phospholipase
A2 (PLA2) (Argiolas and Pisano, 1983; Gil et al., 1991; Joyce-
Brady et al., 1991; Komatsu et al., 1992) and phospholipase
C (PLC) (Okano et al., 1985; Mousli et al., 1989; Perianin and
Snyderman, 1989; Wallace and Carter, 1989; Gusovsky
et al., 1991; Choi et al., 1992). This peptide can also reduce
phosphoinositide separation via the suppression of PLC, or
by the direct interaction of the peptide with phosphoino-
sitides (Nakahata et al., 1989; Wojcikiewicz and Nahorski,
1989; Eddlestone et al., 1995).
The Mastoparan peptide is reported to be capable of
stimulating (Wheeler-Jones et al., 1992) or suppressing
(Nakahata et al., 1989; Joyce-Brady et al., 1991) adenylate
cyclase activity, since this peptide can bind to calmodulin in
a stochiometric proportion of 1:1 (Barnette et al., 1983;
Malencik and Anderson, 1983). Other activities of this
peptide include the augmentation of DNA synthesis due to
the improvement of the GTP/GDP exchange of hetero-
dimeric G proteins; mastoparan also stimulates arachidonic
acid release via a pertussis toxin-sensitive G protein in
Swiss 3T3 cells. Arachidonic acid, like mastoparan, stimu-
lates DNA synthesis in the presence of insulin (Higashijima
et al., 1988; Mousli et al., 1989; Gil et al., 1991; Higashijima
and Ross, 1991; Eddlestone et al., 1995). In addition, Mas-
toparanmay also be capable of lysing eukaryotic cells (Hirai
et al., 1979a, 1979b; Kurihara et al., 1986; Katsu et al., 1990;
Tanimura et al., 1991).
To date, Mastoparan, is the only peptide toxin to be
isolated fromwasp venom that is reported to stimulate therelease of insulin (Daniel et al., 2002). This stimulation
occurs by enhancing intracellular Ca2þ concentration, via
inhibition of the KATP channels (Eddlestone et al., 1995).
Considering the importance of the discovery of anti-
diabetes drugs and the reported action of Mastoparan on
pancreatic beta cells, the study of similar molecules is
fundamental, since this kind of study also increases
knowledge regarding envenomation due to wasp sting
accidents.
Agelaia MP-I (AMP-I) is a mastoparan peptide
(INWLKLGKAIIDAL–NH2), isolated from the venom of the
social wasp venom Agelaia pallipes pallipes, that has 14
amino acid residues and exhibits signiﬁcant hemolytic,
mast cell degranulation, and chemotactic activities
(Mendes et al., 2004; Baptista-Saidemberg et al., 2011). Due
to the characteristics reported for these peptides, we have
investigated the ability of the AMP-I peptide to modulate
the secretion of insulin from langerhans islets isolated from
mice, both in the presence of low and high concentrations
of glucose. The mechanism involved in this modulation is
independent of the KATP and L-type Ca2þ channels.
2. Materials and methods
2.1. Peptide synthesis, puriﬁcation and molecular structure
studies
2.1.1. Peptide synthesis
The peptide (INWLKLGKAIIDAL–NH2) was prepared by
step-wise manual solid-phase synthesis using N-9-
ﬂuorophenylmethoxy-carbonyl (Fmoc) chemistry with
Novasyn TGS resin (NOVABIOCHEM). Side-chain protective
groups included t-butyl for serine and t-butoxycarbonyl for
lysine. Cleavage of the peptide–resin complexes was per-
formed by treatment with triﬂuoroacetic acid/1,2-
ethanedithiol/anisole/phenol/water (82.5:2.5:5:5:5 by
volume), using 10mL/g of complex at room temperature for
2 h. After ﬁltering to remove the resin, anhydrous diethyl
ether (SIGMA) was added at 4 C to the soluble material
causing precipitation of the crude peptide, which was
collected as a pellet by centrifugation at 1000 g for 15min
at room temperature. The crude peptide was solubilized in
water and chromatographed under RP-HPLC using a semi-
preparative column (SHISEIDO C18, 250 mm  10 mm,
5 mm), under isocratic elution with 60% (v/v) acetonitrile in
water [containing 0.1% (v/v) triﬂuoroacetic] at a ﬂow rate of
2 mL/min. The elutionwas monitored at 214 nmwith a UV-
DAD detector (SHIMADZU, mod. SPD-M10A), and each
fraction eluted was manually collected into 1.5 mL glass
vials. The homogeneity and correct sequence of the
synthetic peptides were assessed using a gas-phase
sequencer PPSQ-21A (SHIMADZU) based on automated
Edman degradation chemistry and ESI-MS analysis.
2.1.2. Peptide puriﬁcation
The synthetic peptide was puriﬁed by using a CAPCELL
PACK C-18 UG120 column (10 mm  250 mm, 5 mm,
SHISHEIDO) under isocratic elution with 38% (v/v) MeCN
[containing 0.1% (v/v) TFA]. The elution was monitored at
214 nm, and fractions were manually collected into 5 mL
glass vials.
Fig. 1. Ramachandran plot from Procheck for Agelaia MP-I model.
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MS analyses were conducted on an ion trap/time-of-
ﬂight mass spectrometer (IT-TOF/MS) (Shimadzu, Kyoto,
Japan) equipped with an electrospray ionization source.
The setting conditions for optimized operations were:
positive mode, electrospray voltage 4.5 kV, CDL tempera-
ture 200 C, block heater temperature 200 C, nebulizer gas
(N2) ﬂow of 1.5 L/min, trap cooling gas (Ar) ﬂow of 95 mL/
min, ion trap pressure 1.7  102 Pa, TOF region pressure
1.5  104 Pa, ion accumulation time 50 ms. The auto-
tuning was performed with a Na-TFA solution and
showed the following parameters: for the positive mode,
error 3.1 ppm and resolution 11,000; and for the negative
mode, error 2.3 ppm and resolution 13,000.
2.1.4. Molecular modeling
The search for templates for the AMP-I target sequence
was performed with Blastp (Altschul et al., 1997) and the
alignment (Table 1) was formatted and input into the
program. The structure of the homologous peptide (Mas-
toparan-X) was selected from the Protein Data Bank (PDB)
(Berman et al., 2000), which was solved experimentally by
RMN (PDB ID: 1A13) (Kusunoki et al., 1998). The AMP-I
model was built with restrained-based modeling imple-
mented in MODELLER9v8 (Sali and Blundell, 1993), with
the standard protocol of the comparative protein structure
modeling methodology, by satisfaction of spatial restraints
(Sali and Overington, 1994; Marti-Renom et al., 2000). A
total of 1000 models were created and the best models
were selected according to MODELLER objective function
(Shen and Sali, 2006) and stereochemical analysis with
PROCHECK (Laskowsky et al., 1993). The primary sequence
similarity between the peptide with the template was 65%
(identity 58%). The ﬁnal models were selected with 100%
residues in favored regions of the Ramachandran plot
(Fig. 1), with the best values of the overall G-factor and the
lower values of energy minimization (Table 2). For visual-
ization of the model of AMP-I, the PyMOL program was
used (DeLano, 2002).
2.1.5. Analysis of models
The overall stereochemical quality of theﬁnalmodels for
Agelaia MP-I was assessed by the PROCHECK programTable 1
Amino acid sequences for Agelaia MP-I described by Mendes et al. (2004)
and revisited by Baptista-Saidemberg et al. (2011), Mastoparan described
by Hirai et al. (1979a), and Mastoparan-X described by Hirai et al. (1979b)
aligned by multialign software (http://multalin.toulouse.inra.fr/multalin/
cgi-bin/multalin.pl, accessed in November 24th, 2011). The red color
indicates that the amino acid residue is present in all peptides. The blue
color indicates an amino acid match for at least two peptides. The black
color indicates a difference between the amino acids in the sequences. (For
interpretation of the references to colour in this table legend, the reader is
referred to the web version of this article.)
Peptide Peptide sequence C-Terminal
Mastoparan INLKALAALAKKIL NH2
Mastoparan-X INWKGIAAMAKKLL NH2
Agelaia MP-I INWLKLGKAIIDAL NH2
Consensus INWK.LAA.AKK.L NH2(Koradi et al., 1996). The root mean square deviation (rmsd)
between Ca–Ca atom’s distance was superposed using the
program LSQKAB from CCP4 (Konno et al., 2007). The cutoff
for hydrogen bonds and salt bridges was 3.3 Å. The contact
area for the complexes was calculated using AREAIMOL and
RESAREA (Konno et al., 2007). The root mean square devi-
ation (rmsd) differences from ideal geometries for bond
lengths and bond angles were calculated with X-PLOR
(Krishnakumari and Nagaraj, 1997). The G-factor value is
essentially just log-odds score based on the observed
distributions of the stereochemical parameters. This is
computed for the following properties: torsion angles (the
analysis provided the observed distributions of 4  j,
c1  c2, c  1, c  3, c  4, and u values for each of the 20
amino acid types) and covalent geometry (for the main-
chain bond lengths and bond angles). The average of these
values was calculated using PROCHECK (Koradi et al., 1996).
The Verify-3D measures the compatibility of a protein
modelwith its sequence, usinga3Dproﬁle (Laskowskyet al.,
1993; Kusunoki et al., 1998; Lee et al., 1999).
2.2. AMP-I and insulin secretion
2.2.1. Animals
All experiments were approved by the ethics committee
at the Universidade Estadual de Campinas – UNICAMP
(protocol number 2585-1). The studies were carried out on
90-days-old male Swiss mice obtained from the breeding
colony at UNICAMP and maintained at 22  1 C, on a 12-h
light–dark cycle, with free access to food and water.Table 2
Access PDB code for Agelaia MP-I model presenting the identity and
similarity values between both peptides and the model resolution
method.
Peptide Template Access Identity
(%)
Similarity
(%)
Sequence
resolution
Agelaia
MP-I
Mastoparan-
X (MP-X)
1A13 58 65 MNR
Table 3
Analysis of the stereochemical quality for Agelaia MP-I.
Peptide Ramachandran diagram area G-factor
More
favorable (%)
Additionally
allowed (%)
Favorably
allowed (%)
Not allowed
(%)
Torsion
angle
Covalent
geometry
Total average
Agelaia MP-I 100 0 0 0 0.52 0.09 0.26
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Islets were isolated by collagenase digestion of the
pancreas. For static incubations, four islets were ﬁrst
incubated for 30 min at 37 C in Krebs–bicarbonate (KRB)
buffer with the following composition in mM: 115 NaCl, 5
KCl, 2.56 CaCl2, 1 MgCl2, 10 NaHCO3, 15 HEPES, supple-
mented with 5.6 mM glucose, 3 g/L of bovine serum
albumin (BSA) and equilibrated with a mixture of 95% O2/
5% CO2 to give pH 7.4. This mediumwas then replaced with
fresh buffer, and the islets were incubated for 1 h with 2.8,
11.1 or 22.2 mM glucose without (control group: CTL) or
with AMP-I peptide (AMP-I group). For analysis of whether
the AMP-I peptide interacts with KATP or L-type Ca2þ
channels, the islets were incubated with 2.8 or 11.1 mM
glucose plus 250 mM diazoxide or 10 mM nifedipine. At the
end of the incubation period, the insulin content of the
medium was measured by radioimmunoassay (Ribeiro
et al., 2010).
2.2.3. Statistical analysis
Results are presented as means  S.E.M. for the number
of determinations (n) indicated. The statistical analyses
were carried out using ANOVA Bonferroni, P  0.05 were
performed using GraphPad Prism version 4.00 for
Windows (GraphPad Software, San Diego, CA, USA).Fig. 2. Images generated by MolMol program for the secondary structure
(ribbon) of the Agelaia MP-I peptide. The coil region is the N-terminal, the
green circle represents the amidated C-terminal (COONH2). (For interpre-
tation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)3. Results and discussion
After AMP-I synthesis, fractionation and puriﬁcation,
the ESI-MS analysis of the synthetic peptide presented
a compound with m/z 1566.5 as [M þ H]þ and 784.1 as
[M þ 2H]2þ. The sequencing and homogeneity of AMP-I
was conﬁrmed by mass spectrometry and Edman degra-
dation chemistry (not shown data, for reference see
Baptista-Saidemberg et al., 2011).
AMP-I sequence differs from the original Mastoparan
peptide (from Vespula lewisii), as shown inTable 1. However,
considering the characteristics of the data obtained to
develop the molecular modeling of AMP-I, the results of
biological assays of hemolysis (ED50¼ 6106M) andmast
cell degranulation (ED50¼ 4105M)obtained byBaptista-
Saidemberg et al. (2011), besides in silico classiﬁcation using
physicochemical properties byPCA (Saidemberget al., 2011)
it is possible to conﬁrm that AMP-I is also amastoparan class
peptide.
Agelaia MP-I was modeled using Mastoparan-X as
a template model (Table 3) and the Ramachandran plot
(Fig. 1) shows that the structure obtained for AMP-I was
correct. The 3D structure of AMP-I was shown in Figs. 2 and
3. Fig. 2 demonstrates the amino acid sequence, while Fig. 3
shows the charge distribution along the sequence. These
characteristics of a high percentage of alpha helices, net
charge, and hydrophobicity are in accordance with the PCAgrouping of this peptide, as described recently by
Saidemberg et al. (2011). The molecular modeling of this
peptide is fundamental for understanding its activity in
relation to structure.
Fig. 4 shows insulin secretion in isolated islets incubated
with AMP-I peptide. AMP-I increased glucose-induced
insulin secretion in a dose-dependent manner. Isolated
islets incubated with AMP-I showed enhanced insulin
release at all glucose concentration tested, when compared
with the CTL islets (P < 0.05).
The effects of AMP-I upon pancreatic islets were not due
to lysis, since islets from the AMP-I group at the end of the
experiments were re-incubated under the same conditions
of glucose concentrations, without AMP-I, and showed
a similar secretory function to that observed for CTL islets
(data not shown).
To verify a possible action of AMP-I upon KATP and L-type
Ca2þ channels in pancreatic beta cells function, we used
diazoxide (DZX) and nifedipine (NIF) (Fig. 5). The DZX drug
is a selective ATP-sensitive Kþ channel activator in both
vascular smooth muscle and pancreatic b-cells, and is anti-
hypertensive (Grimmsmann and Rustenbeck, 1998); while
NIF is a L-type Ca2þ channel blocker that induces apoptosis
in human glioblastoma cells (Mayer and Thiel, 2009).
Enhanced insulin release was also observed in the AMP-
I group when incubated with DZX or NIF (P < 0,05). On
other hand, in the CTL group, DZX and NIF completely
inhibited glucose-induced secretion. In contrast to the
results of AMP-I, the Mastoparan peptide has been shown
to increase the intracellular free calcium concentration by
inhibition of ATP-sensitive potassium channels (Eddlestone
et al., 1995), suggesting that different mastoparan peptides
can act by different mechanisms. Mastoparan and its
Fig. 3. Images generated by the PyMol program showing the ribbon structural conformation of the Agelaia MP-I peptide.
Fig. 4. Insulin secretion in response to increasing glucose concentrations, in
combination or not with 10 mM Agelaia MP-I. Data represents mean  SEM,
n ¼ 8. *P < 0.05 vs CTL.
Fig. 5. Insulin secretion in response to 2.8 (G2.8) and 11.1 (G11.1) mM
glucose with or without 10 mM Agelaia MP-I. Data represents mean  SEM,
n ¼ 8. *P < 0.05 vs CTL.
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(Weingarten et al., 1990; Wakamatsu et al., 1992), therefore
due to the similarity of AMP-I with Mastoparan-X, a very
well described G protein interacting peptide (Sukumar and
Higashijima, 1992; Wakamatsu et al., 1992), this is a very
good clue about the mechanism of action of AMP-I, since
several important sites regulating stimulus-secretion
coupling and release of insulin from pancreatic beta-cells
are modulated by G proteins (Robertson et al., 1991).
The principal component analysis (PCA) classiﬁcation,
described by Saidemberg et al. (2011), of the Mastoparans
also indicates that some edge peptides from this large class,
in addition to having similar general physico-chemical
properties, can show some superposition with other
peptide groups. Therefore, besides having the same general
activities, different mastoparans can have different mecha-
nisms of action andproperties. This feature is closely related
to its structure and physico-chemical properties, which can
lead to the opening of new structure–function relationship
studies of peptides for pharmacological applications.
4. Conclusion
Agelaia MP-I, like the Mastoparan peptide, is a peptide
capable of interacting with different components of cells
(phospholipids, receptors, ionic channels) and promoting
the degranulation of different granulocytes. As such, AMP-I
showed a positive and non-lytic effect upon pancreatic beta
cell function. In contrast to Mastoparan, AMP-I did not
affect KATP nor L-type Ca2þ channel activity in pancreatic
beta cells, suggesting a different mechanism for this
peptide, possibly by a G protein interaction due to the
structural and physicochemical similarity of this peptide
with Mastoparan-X, as obtained by modeling. This study
may open interesting new structure–activity relationship
perspectives for peptides with pharmacological interest for
future studies related to metabolic endocrine disease.Acknowledgments
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